12.52
-0.32 (-2.46%)
| Penutupan Terdahulu | 12.83 |
| Buka | 12.80 |
| Jumlah Dagangan | 172,843 |
| Purata Dagangan (3B) | 227,470 |
| Modal Pasaran | 1,625,133,824 |
| Harga / Jualan (P/S) | 16.48 |
| Harga / Buku (P/B) | 3.50 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Aug 2026 |
| Margin Operasi (TTM) | -633.21% |
| EPS Cair (TTM) | -1.24 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -6.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 27.34% |
| Nisbah Semasa (MRQ) | 0.960 |
| Aliran Tunai Operasi (OCF TTM) | -42.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.46 M |
| Pulangan Atas Aset (ROA TTM) | -4.85% |
| Pulangan Atas Ekuiti (ROE TTM) | -21.31% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Mesoblast Limited | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 4.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -2.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | -5.0 |
| AI Insight | NA |
| Purata | -0.71 |
|
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 0.06% |
| % Dimiliki oleh Institusi | 3.10% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lazari Capital Management, Inc. | 30 Jun 2026 | 47,421 |
| Rialto Wealth Management, Llc | 30 Jun 2026 | 46,500 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
AI Analisis Teknikal
Buka tab Teknikal untuk menjana analisis terkini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |